THE ROLE OF TRANSIENT RECEPTOR POTENTIAL CHANNELS IN
JOINT DISEASES

O. Krupkova1*, J. Zvick1 and K. Wuertz-Kozak1,2,3,4

1 Department of Health Sciences and Technology, Institute for Biomechanics, ETH Zurich, Zurich, Switzerland
2 Department of Health Sciences, Institute of Sociology of Health and Physical Activity, University of Potsdam, Potsdam, Germany
3 Schön Clinic Munich Harlaching, Munich, Germany
4 Spine Centre, Academic Teaching Hospital and Spine Research, Paracelsus Medical University, Salzburg, Austria

Abstract

Transient receptor potential channels (TRP channels) are cation selective transmembrane receptors with diverse structures, activation mechanisms and physiological functions. TRP channels act as cellular sensors for a plethora of stimuli, including temperature, membrane voltage, oxidative stress, mechanical stimuli, pH and endogenous as well as exogenous ligands, thereby illustrating their versatility. As such, TRP channels regulate various functions in both excitable and non-excitable cells, mainly by mediating Ca\textsuperscript{2+} homeostasis. Dysregulation of TRP channels is implicated in many pathologies, including cardiovascular diseases, muscular dystrophies and hyperalgesia. However, the importance of TRP channel expression, physiological function and regulation in chondrocytes and intervertebral disc (IVD) cells is largely unexplored. Osteoarthritis (OA) and degenerative disc disease (DDD) are chronic age-related disorders that significantly affect the quality of life by causing pain, activity limitation and disability. Furthermore, currently available therapies cannot effectively slow-down or stop progression of these diseases. Both OA and DDD are characterised by reduced tissue cellularity, enhanced inflammatory responses and molecular, structural and mechanical alterations of the extracellular matrix, hence affecting load distribution and reducing joint flexibility. However, knowledge on how chondrocytes and IVD cells sense their microenvironment and respond to its changes is still limited. In this review, we introduced six families of mammalian TRP channels, their mechanisms of activation as well as activation-driven cellular consequences. We summarised the current knowledge on TRP channel expression and activity in chondrocytes and IVD cells and the significance of TRP channels as therapeutic targets for the treatment of OA and DDD.

Keywords: Transient receptor potential channels, degenerative disc disease, osteoarthritis, nociception, mechanosensing, osmosensing, inflammation, calcium.

*Address for correspondence: Olga Krupkova, ETH Zurich, Hoenggerbergring 64, 8093 Zurich, Switzerland.
Telephone: +41 44 633 2901 Email: okrupkova@ethz.ch

Introduction

Transient receptor potential (TRP) channels are cell surface receptors involved in mechanosensing, osmosensing and hyperalgesia. Dysregulation of TRP channels affects mechanical, osmotic and inflammatory sensitivity in various cell types. As evidence suggests that impairment of TRP channels in chondrocytes and intervertebral disc (IVD) cells may contribute to joint degeneration and pain, these channels represent potential therapeutic targets. However, the importance and role of specific TRP channels in chondrocytes and IVD cells is not yet fully explored. Therefore, the aims of this review were (1) to summarise the current knowledge on TRP channel expression and activity in chondrocytes and IVD cells and (2) to discuss the significance of TRP channels as therapeutic targets in the treatment of joint diseases, particularly osteoarthritis (OA) and degenerative disc disease (DDD).

Degenerative joint diseases

Degenerative joint diseases, such as OA and DDD, are chronic age-related disorders that significantly affect the quality of life.

OA is the most prevalent form of skeletal disease, representing a leading cause of disability during middle and old age. OA causes degenerative destruction of articular cartilage and joint integrity, being associated with pain (Lawrence et al., 2008). Joint
structures, such as capsule, synovium and ligaments are innervated by sensory nerves, which can be damaged or sensitised by a variety of chemicals. This results in two types of pain: nociceptive pain, caused by a neural sensitisation due to tissue damage and neuropathic pain, resulting from damaged nerves (Thakur et al., 2014). OA affects around 40% of people above 70 years of age (Lawrence et al., 2008).

DDD is a progressive loss of function of IVDs and the major contributor to low back pain (LBP), another significant cause of disability in industrialised countries, which affects more than 80% of people at least once in their life (Fai and Sundaram, 2004; Roberts et al., 2006). Although DDD does not always correlate with the presence and severity of LBP, an IVD-related problem is generally accepted to be the most common cause of LBP (Schwarzer et al., 1995), as degenerated IVDs are frequently invaded by newly-formed nociceptive nerves (Sivan et al., 2014; Urban et al., 2004). Discogenic nociceptive pain is caused by a neuronal sensitisation, due to internal IVD disruption (Roberts et al., 2006), while neuropathic pain arises from neuronal damage and inflammation caused by IVD-related compression of nerve roots (Cramer and Darby, 1997; Ito and Creemers, 2013).

Both OA and DDD are characterised by an age-related reduction in tissue cellularity and molecular, structural and mechanical alterations of the extracellular matrix (ECM). These alterations progressively change the load distribution, reducing the joint flexibility and causing pain (Galbusera et al., 2014; Le Maitre et al., 2007; Neogi, 2013). Furthermore, both tissues undergo the so-called “inflammaging”, i.e. low-grade, aging-associated chronic inflammation (Franceschi and Bonafe, 2003; Mobasher et al., 2015). As effective treatments are not available, both OA and DDD show high rates of reoccurrence and slow recovery, often becoming chronic (Henschke et al., 2008; Hoy et al., 2010a; Hoy et al., 2010b). With an ageing society and increasing obesity, the incidence and prevalence of OA and DDD is expected to rise, hence further extending the burden on the society and the economy alike (Adams and Roughley, 2006; Galbusera et al., 2014; Peat et al., 2001; Wieser et al., 2011). However, biological mechanisms underlying painful OA and DDD are not sufficiently understood to allow for an accurate therapeutic targeting. Therapies used to manage OA and DDD are, up to the present, limited to pain control, with no agent to date approved for the prevention or treatment of disease progression (Sokolove and Lepus, 2013). However, because of the high potential benefit of such treatments, the research community is actively working on the elucidation of underlying pathobiological mechanisms, as well as on the subsequent identification of novel therapeutic candidates. Over recent years, a new group of possible candidates has emerged, the TRP channels.

**Transient receptor potential channels**

TRP channels form a superfamily of cation-selective-transmembrane receptors with diverse structure, activation mechanisms and physiological functions. More than 50 TRP channels have been identified.
in many species, with 28 TRP channels discovered in mammals. TRP channels contain six membrane-spanning domains, intracellular N- and C-termini and a pore domain between the fifth and the sixth segment, especially permeable for Ca\(^{2+}\) ions (Liu and Montell, 2015). TRP channels mainly function as sensors for various physical and chemical stimuli, such as temperature, pH, plant secondary metabolites, osmolarity and mechanical stress, and regulate cellular responses to these stimuli. As such, they are important for cellular signal transduction, survival and adaptation to environmental changes (Montell et al., 2002; Wu et al., 2010).

Seven families of TRP channels are identified, classifying TRP channels based on their sequence homology and topological differences: TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPV (vanillin), TRPP (polycystin), TRPML (mucolipin) and TRPN (nompC), the latter not being present in mammals. Apart from TRPA, every subfamily has several members (Wu et al., 2010). Most of the TRP channels form tetramers with either homotetrameric or heterotetrameric configurations, with heterotetramers likely assembling within the same subfamily (Gees et al., 2010). Consequently, a large variety of different TRP channel combinations, with unique properties and sensitivity to numerous activation stimuli (Fig. 1), exists (Gees et al., 2010; Strubing et al., 2001).

Associations between TRP channels and human diseases are described. The disorders caused by mutations in TRP genes include focal segmental glomerulosclerosis (TRPC6), autosomal recessive congenital stationary night blindness (TRPM1), adult polycystic kidney disease (TRPP1), mucolipidosis type IV (TRPML1) and skeletal disorders, such as brachyolmia or metatropic dysplasia (TRPV4). Evidence suggests that hereditary and acquired abnormalities in TRP channel function are implicated in numerous other diseases, among which cardiovascular diseases, muscle dystrophies and pain-related pathologies are the most prominent (Everett, 2011; Nilius and Owsianik, 2010). However, the exact mechanisms underlying TRP channel involvement in human diseases are largely unknown. This uncertainty is partially related to the fact that TRP channels are commonly activated by multimodal mechanisms (Rohacs, 2013; Venkatácthalam and Montell, 2007; Zheng, 2013). As most of the known TRP agonists and antagonists simultaneously interact with multiple TRP channels (Ramsey et al., 2006), studying their biological functions is challenging. Interestingly, TRP channels do not always locate to the plasma membrane as functional channels, but may have other intracellular roles yet to be fully identified.

Studies performed in TRP-deficient mice reveal important information on the role of TRP channels in mammalian physiology (Desai and Clapham, 2005). TRP channel knockout (KO) or knockdown (KD) often cause impairment in sensing of innocuous and noxious environmental stimuli, such as heat, cold or taste. Interestingly, most KO phenotypes are quite moderate, suggesting that TRP isoforms can compensate for the lack of a specific channel (Birnbaumer, 2009). The phenotypes of TRP-deficient mice created up to date are summarised in Table 1, and described in more detail in the publications by David E. Clapham and colleagues (Desai and Clapham, 2005; Wu et al., 2010). Although rodent studies provide valuable data, simple translation of this knowledge to human medicine is not always possible due to the different anatomy and physiology of rodents. In addition, tools to study TRP channel function in vivo are largely unavailable.

In vitro and in vivo studies reveal that TRP channels are involved in modulation of cellular homeostasis, mainly by regulating Ca\(^{2+}\) influx in a variety of excitable and non-excitable cell types (Gees et al., 2010; Nilius and Owsianik, 2011). TRP channels are not only located in the plasma membrane, but also in intracellular organelles, such as sarco/endoplasmic reticulum and endosomes, lysosomes or autophagosomes (Grimm et al., 2012). Therefore, TRP channels can function as (1) Ca\(^{2+}\) entry sites on the plasma membrane, (2) electrogenic mediators changing the membrane polarisation or (3) Ca\(^{2+}\) release channels in intracellular organelles (Gees et al., 2010). TRP channels differ in their pore size and permeability for Ca\(^{2+}\), depending on their pore structure. Although most TRP channels are Ca\(^{2+}\) permeable, their selectivity varies among the different members, with \(P_{Ca}/P_{Na}\) ratios ranging from <1 for TRPM1 to >100 for TRPV5 and TRPV6 (Gees et al., 2010).

TRP channels activity is modulated by diverse extracellular and intracellular stimuli sensed through a single or multistep process. Assignment of a TRP channel to a subfamily does not always determine its mode of activation, as different TRP channels can be regulated through the same stimulus (Montell et al., 2002; Zheng, 2013). Various agonists and antagonists of mammalian TRP channels have been reported (Numata et al., 2011). In addition, TRP channels can be modulated by intracellular phospholipase C (PLC) signalling. Apart from direct activation and inhibition, the function of TRP channels is also regulated on the gene expression level and through their membrane trafficking (Bezzerides et al., 2004; Numata et al., 2011; Schmidt et al., 2009). Multiple mechanisms of TRP channel modulation were proposed in in vitro studies; however, it is still unclear how these data correspond to an in vivo situation.

Emerging role of TRP channels in joint diseases
Several TRP channels are expressed in joints, but their potential biological function and therapeutic relevance is not yet fully understood. The presence and severity of pain in OA and DDD is associated with cellular decline, ECM degradation and activity of inflammatory cytokines (Aoki et al., 2014; Grassel, 2014; Halliday et al., 1998; Pecchi et al., 2014). It has
Table 1a. Phenotypes of TRP-deficient mice. GABA = gamma-aminobutyric acid, OA = osteoarthritis, DRG = dorsal root ganglion, IFNγ = interferon gamma, IL-12 = interleukin 12, ROS = reactive oxygen species, CA1 = carbonic anhydrase 1.

<table>
<thead>
<tr>
<th>TRP channel</th>
<th>Phenotype</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRPA1&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>impaired responses to noxious cold and oxidative stress, reduced nociception hypersensitivity in arthritic joints, suppressed inflammatory and fibrogenic reaction in cornea after chemical injury, decreased basal levels of pro-inflammatory mediators</td>
<td>Bessac et al., 2008; Horvath et al., 2016; Karashima et al., 2009; Kun et al., 2014; Kwan et al., 2006; Okada et al., 2014</td>
</tr>
<tr>
<td>TRPC1&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>decreased endothelial transmigration of neutrophils, decreased inflammatory response and ineffective bacterial clearance, no pulmonary hypertension response to chronic hypoxia and reduced vascular muscularisation</td>
<td>Lindemann et al., 2015; Malcz-zyk et al., 2013; Zhou et al., 2015</td>
</tr>
<tr>
<td>TRPC2&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>altered responses to pheromones, TRPC2 is not functionally expressed in humans</td>
<td>Beny and Kimchi, 2016; Desai and Clapham, 2005; Leybold et al., 2002; Stowers et al., 2002; Wu et al., 2014</td>
</tr>
<tr>
<td>TRPC3&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>defective normal functioning of the hind paws, no effect on agonist-mediated vasoconstriction or nonspecific depolarisation, decreased behavioral manifestations of seizures</td>
<td>Hartmann et al., 2008; Kochukov et al., 2013; Phelan et al., 2017</td>
</tr>
<tr>
<td>TRPC4&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>impaired endothelium-dependent relaxation of blood vessels, changes in microvascular permeability and GABA release from thalamic interneurons</td>
<td>Freichel et al., 2004; Tiruppathi et al., 2006; Tsvilovskyy et al., 2009</td>
</tr>
<tr>
<td>TRPC5&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>changes in adaptation to innocuous cold in the peripheral nervous system, severe daily blood pressure fluctuation, impaired blood pressure stability, reduced seizures and minimal seizure-induced neuronal cell death in hippocampus</td>
<td>Lau et al., 2016; Phelan et al., 2013; Zimmermann et al., 2011</td>
</tr>
<tr>
<td>TRPC6&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>increased smooth muscle tone, reduced albuminuria after 28 d infusion of angiotensin II</td>
<td>Dietrich et al., 2003; Eckel et al., 2011</td>
</tr>
<tr>
<td>TRPC7&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>reduction in pilocarpine-induced increase in gamma waves preceding seizures</td>
<td>Phelan et al., 2014</td>
</tr>
<tr>
<td>TRPV1&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>loss of function in DRG, altered mechanical and osmotic function in urinary bladder, impaired nociception, pain and fever responses, attenuated ear swelling and expression of neurotrophin mRNA after painting ears with 5 % formalin</td>
<td>Birder et al., 2002; Caterina et al., 2000; Davis et al., 2000; Fang et al., 2014; Iida et al., 2005; Ishikura et al., 2015; Wakabayashi et al., 2017</td>
</tr>
<tr>
<td>TRPV2&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>increased perinatal lethality, reduced adult body weight (conflicting: obese and insulin resistant when fed with high fat diet), improved cardiac recovery after permanent left anterior descending artery occlusion, heart specific KO: decreased induction of thermogenic genes in brown adipocytes and cold intolerance</td>
<td>Entin-Meer et al., 2017; Katanosaka et al., 2014; Park et al., 2011; Sun et al., 2016</td>
</tr>
<tr>
<td>TRPV3&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>deficits in responses to innocuous and noxious heat, delayed oral wound closure</td>
<td>Aijima et al., 2015; Moqrich et al., 2005</td>
</tr>
<tr>
<td>TRPV4&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>impaired osmotic regulation and pressure sensation, impaired responses to acid-induced pain, increased knee OA scores, reduced spontaneous cage activity, increasing weight gain and adiposity, disturbed signaling during noxious stimulation of the bladder, no increase of c-fos during bladder inflammation, lower mean arterial pressure baseline – potential involvement in angiotensin II-induced endothelial dysfunction, impaired thermotaxis of sperm, cartilage specific KO: reduced age-related OA</td>
<td>Hamano et al., 2016; Janssen et al., 2016; Liedtke and Friedman, 2003; Mizuno et al., 2003; Nishijima et al., 2014; O’Conor et al., 2013; O’Conor et al., 2016; Suzuki et al., 2003</td>
</tr>
</tbody>
</table>
Table 1b. Phenotypes of TRP-deficient mice. GABA = gamma-aminobutyric acid, OA = osteoarthritis, DRG = dorsal root ganglion, IFNγ = interferon gamma, IL-12 = interleukin 12, ROS = reactive oxygen species, CA1 = carbonic anhydrase 1.

<table>
<thead>
<tr>
<th>TRP channel</th>
<th>Phenotype</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRPV5-/-</td>
<td>reduced bone thickness and renal calcium reabsorption</td>
<td>Hoenderop et al., 2003; Renkema et al., 2005; van der Eerden et al., 2016</td>
</tr>
<tr>
<td></td>
<td>increased intestinal calcium hyperabsorption</td>
<td></td>
</tr>
<tr>
<td></td>
<td>hypercalcuria</td>
<td></td>
</tr>
<tr>
<td></td>
<td>increased age-related changes in trabecular and cortical bone mass</td>
<td></td>
</tr>
<tr>
<td>TRPV6-/-</td>
<td>destruction of bone microarchitecture</td>
<td>Bianco et al., 2007; Chen et al., 2014; Suzuki et al., 2008; Weissgerber et al., 2012</td>
</tr>
<tr>
<td></td>
<td>decreased foetal blood Ca²⁺ level</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ca²⁺ deficiency and abnormal development</td>
<td></td>
</tr>
<tr>
<td></td>
<td>hypofertility in males</td>
<td></td>
</tr>
<tr>
<td>TRPM1-/-</td>
<td>no b-wave in bipolar cells</td>
<td>Morgans et al., 2009; Shen et al., 2009; Ueno et al., 2013; Xiong et al., 2013</td>
</tr>
<tr>
<td></td>
<td>no accumulation of melanoma-associated retinopathy autoantibodies on intracellular epitope of TRPM1</td>
<td></td>
</tr>
<tr>
<td>TRPM2-/-</td>
<td>reduced sensation of non-noxious warm temperatures</td>
<td>Knowles et al., 2011; Liu et al., 2013; So et al., 2015; Tan and McNaughton, 2016; Ye et al., 2014</td>
</tr>
<tr>
<td></td>
<td>higher mortality and increased bacterial burdens already at early stage of listeria infection, and reduced production of IFN-γ and IL-12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>delayed increase in zinc concentration, ROS generation, CA1 pyramidal neuronal death and post-ischemic memory impairment after transient ischemic brain injury</td>
<td></td>
</tr>
<tr>
<td></td>
<td>anti-allodynic effect in inflammatory and neuropathic pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>reduced salivary gland function after radiotherapy</td>
<td></td>
</tr>
<tr>
<td>TRPM3-/-</td>
<td>deficits in noxious heat avoidance</td>
<td>Vriens et al., 2011</td>
</tr>
<tr>
<td></td>
<td>development of inflammatory heat hyperalgesia</td>
<td></td>
</tr>
<tr>
<td>TRPM4-/-</td>
<td>impaired chemokine-dependent dendritic cell migration</td>
<td>Barbet et al., 2008; Demion et al., 2014; Mathar et al., 2014</td>
</tr>
<tr>
<td></td>
<td>shortened ventricular action potential</td>
<td></td>
</tr>
<tr>
<td></td>
<td>increased B-adrenergic inotropy of the heart muscle</td>
<td></td>
</tr>
<tr>
<td>TRPM5-/-</td>
<td>impaired response to sweet, umami and bitter tastes</td>
<td>Zhang et al., 2003; Larsson et al., 2015</td>
</tr>
<tr>
<td></td>
<td>improved glucose tolerance</td>
<td></td>
</tr>
<tr>
<td>TRPM6-/-</td>
<td>homozygous deficiency is in most cases lethal</td>
<td>Walder et al., 2009; Woudenberg-Vrenken et al., 2011</td>
</tr>
<tr>
<td>TRPM7-/-</td>
<td>decreased hyperplasia associated with increased adult cardiomyocyte size</td>
<td>Sah et al., 2013</td>
</tr>
<tr>
<td>TRPM8-/-</td>
<td>absence of jumping after icilin injection</td>
<td>Bautista et al., 2007; Colburn et al., 2007; Dhaka et al., 2007</td>
</tr>
<tr>
<td></td>
<td>diminished cold response</td>
<td></td>
</tr>
<tr>
<td></td>
<td>decreased discrimination between cold and warm surfaces</td>
<td></td>
</tr>
<tr>
<td>TRPP1-/-</td>
<td>abnormal male reproductive tract</td>
<td>Boulter et al., 2001; Li et al., 2017; Nie and Arend, 2013</td>
</tr>
<tr>
<td></td>
<td>bone specific KO: reduced long bone weight and length</td>
<td></td>
</tr>
<tr>
<td>TRPP2-/-</td>
<td>cysts in kidney and pancreas</td>
<td>Boulter et al., 2001; Kim et al., 2009; Nie and Arend, 2014; Wu et al., 1998</td>
</tr>
<tr>
<td></td>
<td>defects in cardiac septum</td>
<td></td>
</tr>
<tr>
<td></td>
<td>focal haemorrhage</td>
<td></td>
</tr>
<tr>
<td></td>
<td>total body edema</td>
<td></td>
</tr>
<tr>
<td></td>
<td>male reproductive tract</td>
<td></td>
</tr>
<tr>
<td></td>
<td>embryonic lethality</td>
<td></td>
</tr>
<tr>
<td>TRPML1-/-</td>
<td>dense inclusion bodies in all cell types in brain</td>
<td>Chandra et al., 2011; Micsenyi et al., 2009; Venugopal et al., 2007</td>
</tr>
<tr>
<td></td>
<td>glial cell activation and reduced myelination</td>
<td></td>
</tr>
<tr>
<td></td>
<td>retinal degeneration</td>
<td></td>
</tr>
<tr>
<td></td>
<td>neurological defects</td>
<td></td>
</tr>
<tr>
<td></td>
<td>impairment in basal and histamine-stimulated gastric acid secretion and reduced levels of gastric proton pump</td>
<td></td>
</tr>
<tr>
<td></td>
<td>enlarged parietal cells, abnormal lysosomes and canalicular membrane</td>
<td></td>
</tr>
<tr>
<td>TRPML2-/-</td>
<td>reduced secretion of CCL2</td>
<td>(Sun et al., 2015)</td>
</tr>
<tr>
<td>TRPML3-/-</td>
<td>unknown</td>
<td></td>
</tr>
</tbody>
</table>
been shown that ECM changes and hyperalgesia may correlate with dysregulation of TRP channels, suggesting that TRP channels are involved in sensing and regulating inflammation, mechanical and osmotic stress as well as pain in joints (Gavenis et al., 2009). Current knowledge on TRP channel expression and activity in nociceptors, chondrocytes and IVD cells is summarised below and in Fig. 2.

TRP channels in joint pain signalling and inflammation

Dysregulated sensory responses to noxious, irritant and inflammatory stimuli underlie chronic diseases, including OA and DDD. Interestingly, in both OA and DDD, the severity of pain does not always correlate with macroscopic structural evidence of joint/IVD damage. This is explained by the fact that pain perception comprises a complex series of neurophysiologic events involving stimulation, tissue response, transmission of pain signal and subsequent modulation of these at both peripheral and central levels (Ito and Creemers, 2013; Schäible, 2012).

Inflammatory cytokines are important regulators of these pain mechanisms and their presence is associated with inflammatory pain arising from articular joints and IVDs (Ito and Creemers, 2013; Wuertz et al., 2012; Zhang et al., 2013). Interleukin-1 beta (IL-1β) and tumour necrosis factor alpha (TNF-α) contribute to disease progression and pain, by acting directly not only as nociceptive triggers, but also by inducing generation of other potentially nociceptive molecules, including nitric oxide and prostaglandin E (Liu et al., 2016; Risbud and Shapiro, 2014). IL-1β and TNF-α are secreted by cells of the immune system, such as macrophages, and by a variety of other cell types, including chondrocytes, annulus fibrosus (AF) and nucleus pulposus (NP) cells, regulating host responses to stress, inflammation, infection or trauma (Berenbaum, 2013; Johnson et al., 2015; Oda et al., 2004; Vo et al., 2016). IL-1β and TNF-α are known to activate nuclear factor κB (NF-κB), c-Jun N-terminal protein kinase (JNK) and/or p38 mitogen-activated protein kinase (MAPK) (Hoyland et al., 2008; McNulty et al., 2009; Vo et al., 2013; Wang et al., 2015; Wilusz et al., 2008). Activation of these kinases results in the transcription of inflammatory and catabolic genes, such as interleukins, collagenases [matrix metalloproteinases (MMPs)], aggrecanases (ADAMTS) and molecules that promote pain, including cyclooxygenase 2 (COX-2), nerve growth factor (NGF) and inducible nitric oxide synthase (iNOS) (Johnson et al., 2015; Ricciotti and FitzGerald, 2011; Vo et al., 2013; Wuertz and Haglund, 2013). In addition to the catabolic and pro-inflammatory effects, IL-1β and TNF-α can influence cell senescence, autophagy and expression of genes involved in chondrocyte proliferation (Goldring and Otero, 2011; Risbud and Shapiro, 2014). As such, IL-1β and TNF-α play a significant role in cartilage and IVD homeostasis, but the mechanisms involved in transduction and modulation of their signal are not yet well-understood (Freemont et al., 1997; Kepler et al., 2013; Sokolove and Lepus, 2013; Zhang and An, 2007). The expression and activity of TRP channels is found altered in in vitro and in vivo studies on painful joint disorders, suggesting that signals provided by pro-inflammatory cytokines may be transduced and modulated through TRP channels. Current results and hypotheses on how inflammation can regulate or be regulated by TRP channels are given below and in Fig. 2.

TRPA

TRPA1, currently the only known member of the TRPA family, is possibly involved in the development of joint-associated chronic pain and mechanical hyperalgesia. TRPA1 is widely expressed in sensory neurons, such as those in nociceptive dorsal root ganglia (DRG), and in non-neuronal cells including epithelial cells, keratinocytes and chondrocytes (Atayan et al., 2009; Boesmans et al., 2011; Buch et al., 2013; Nummenmaa et al., 2016). Both neuronal and non-neuronal TRPA1 can be involved in the development of pain.

TRPA1 mediates mechanical hyperalgesia upon planter injection of TNF-α in mice (Fernandes et al., 2011) and mechanical hyperalgesia is reduced upon the application of the TRPA1 antagonist HC-030031 (Eid et al., 2008b). In addition, hyperalgesia is also attenuated in the TRPA1−/− mouse model of chronic arthritis, suggesting the involvement of neuronal TRPA1 in OA pain (Eid et al., 2008; Horváth et al., 2016). In neurons, TRPA1 often co-localises with TRPV1, a TRP channel contributing to nerve sensitisation and hyperalgesia (Andrei et al., 2016; Brain, 2011), and both TRPA1 and TRPV1 are required for bradykinin-induced thermal hyperalgesia (Bautista et al., 2006). Therefore, TRPA1 and TRPV1, highlighted in more detail in the next subchapter, seem to integrate noxious stimuli and regulate responses to pain and neurogenic inflammation (Fernandes et al., 2012). TRPA1 is also expressed in human OA chondrocytes and its expression can be upregulated by pro-inflammatory cytokines (Bautista et al., 2006; Hatano et al., 2012a; Horváth et al., 2016). Interestingly, we have recently detected similar response patterns in human IVD cells (Zvick, 2017). In IL-1β-stimulated OA chondrocytes, the application of a TRPA1 antagonist reduced the expression of inflammatory and catabolic genes and proteins, indicating that TRPA1 contributes to transmission of chondrocyte inflammation (Nummenmaa et al., 2016). Mechanisms by which inflammatory mediators influence the activity of TRPA1 gene were investigated in synoviocytes. Inflammation-induced TRPA1 gene expression in synoviocytes increases via NF-κB signalling and activation of the transcription factor hypoxia-inducible factor-1α (HIF1α), which binds to specific regions in the TRPA1 gene (Hatano et al., 2012b). TRPA1 expression and activity in sensory neurons and non-neuronal cells is not only modulated by pro-inflammatory cytokines, but also...
by neuropeptides and ROS (Bautista et al., 2006; Hatano et al., 2012a; Nilius et al., 2012; Nummenmaa et al., 2016; Sullivan et al., 2015; Yu and Ouyang, 2009), all of which are commonly elevated in OA synovial fluid and degenerated IVDs (Bandell et al., 2004; Feng et al., 2017; Nummenmaa et al., 2016). These data suggest that blockage of TRPA1 may be beneficial in reducing chronic pain and inflammation associated with joint pathologies.

**TRPV**

TRPV1, also known as the capsaicin receptor, is one of the six members of the TRPV family (TRPV1, TRPV2, TRPV3, TRPV4, TRPV5 and TRPV6). TRPV1 is mainly expressed in sensory neurons and trigeminal ganglions, but also in multiple non-neuronal cell types. As TRPV1 protein expression is increased in synovium of OA knee joints in a rat OA model and as mechanical hyperalgesia is reversed upon TRPV1 blockage (Kelly et al., 2015), TRPV1 is possibly involved in painful OA. The association of TRPV1 with OA is also shown in a murine model, where the upregulation of TRPV1 in sensory neurons – through complete Freund’s adjuvant (CFA) – contributes to nociception and severity of knee OA (Chen et al., 2009). The authors show that TRPV1 is co-expressed

---

**Fig. 2.** Function of TRP channels in joint diseases. The gene expression of TRPA1 in cartilaginous tissues can be stimulated by inflammatory cytokines and regulated by NF-κB and HIF-α. Active TRPA1 further promote inflammatory responses. The expression of TRPV4 is influenced by osmolarity and regulated by ERK1/2. Active TRPV4 is implicated in cellular volume change, aggrecan homeostasis and inflammatory responses. Ca\(^{2+}\) influx through TRPV4 can be directly stimulated by physiological loading, promoting expression of anabolic and anti-catabolic genes. Evidence suggests that other TRP channels also contribute to inflammation and load-induced effects in degenerative disc disease and osteoarthritis, but their involvement is not completely understood. uk = exact mechanism unknown.
with p-ERK, indicating the involvement of ERK in TRPV1-mediated effects. Furthermore, activation of ERK in sensory neurons of TRPV1−/− mice is reduced compared to wild-type (WT) mice and these changes correlate with changes in pain behaviour and joint histopathology (Chen et al., 2009). In the spine, TRPV1 is localised in dorsal root ganglion (DRG) neurons that innervate IVDs. TRPV1 expression and activity in DRGs increases after inflammatory stimulation, possibly causing chronic inflammatory pain, including thermal hyperalgesia and mechanical allodynia in rats (Yu et al., 2008). It is shown that not only the plasma membrane, but also the endoplasmic reticulum (ER) of DRG neurons contains TRPV1, which is involved in Ca2+ depletion from ER and ER stress response (Gallego-Sandin et al., 2009). ER TRPV1 may also serve as pool for rapid TRPV1 mobilisation to the plasma membrane, since ER-located TRPV1 channels are quickly inserted into the plasma membrane in reaction to neurotrophins, such as NGF, providing an explanation for inflammatory sensitisation and hyperalgesia (Stein et al., 2006; Zhang et al., 2005). In addition, protein kinase C (PKC) signalling is involved in the exocytosis of TRPV1 to the cell surface (Morenilla-Palao et al., 2004). TRPV1 is also expressed in chondrocytes (Gavenis et al., 2009) and IVD cells (unpublished data), but its exact function and mechanisms of regulation in these cell types are yet unknown. TRPV1 is activated by acidic pH (Dhaka et al., 2009), which is an important factor in chondrocyte and IVD homeostasis. Lactic acid accumulates in degenerative joints and IVDs as a result of impaired fluid transport (Roberts et al., 2006; Urban et al., 2004), altering the cellular repair capacity and promoting pain (Le Maitre et al., 2007). As a putative sensor for acidic pH, over-stimulated or up-regulated TRPV1 can be possibly involved in the responses of chondrocytes and IVD cells to acidity. Therefore, TRPV1 inhibition or desensitisation may be beneficial against pH-induced hyperalgesia.

Evidence suggests that another member of the TRPV family, namely TRPV4, is functionally expressed in bovine IVD cells stimulated by pro-inflammatory cytokines (Walter et al., 2016). TRPV4 could also be involved in mediating thermal hyperalgesia and inflammatory swelling in inflamed joints (Keeble et al., 2005). Apart from hyperalgesia, TRPV4 regulates transduction of mechanical and osmotic signals activated by load and swelling in chondrocytes and IVD cells, as outlined in detail below (Guler et al., 2002; Kohler and Hoyer, 2007; Phan et al., 2009; Strotmann et al., 2000b; Todaka et al., 2004).

TRPC

Several members of the TRPC family, classified into TRPC1, TRPC2, TRPC3/6/7 and TRPC4/5 subfamilies, may be of relevance in pain signalling and inflammation in joints. The TRPC family includes non-selective Ca2+ permeable channels that share the potentiated stimulation by G-protein coupled receptor (GPCR) and phospholipase C (PLC) (Freichel et al., 2004; Vazquez et al., 2004). Most TRPC channels are widely expressed and a given cell type usually contains more than one TRPC isoform (Gees et al., 2010).

TRPC4 is expressed in various cells of the nervous system, as well as in endothelial cells, where it is involved in regulation of blood vessel tone (Freichel et al., 2004; Qian et al., 2002). Moreover, it contributes to axonal regeneration after DRG nerve injury. Suppression of TRPC4 inhibits neuronal growth, while overexpression of TRPC4 rescues it (Wu et al., 2008). Although axonal growth is favourable in neuronal regeneration, it is not desired in aneural cartilage and IVD tissue, where enhanced neuronal growth, possibly because of dysregulation of TRPC4 expression and activity, may aggravate pain. Interestingly, the activation of TRPC5 in inflamed joints may also be associated with an endogenous anti-inflammatory/analgesic pathway. In mice, genetic deletion or pharmacological blockage of TRPC5 results in enhanced joint inflammation and hyperalgesia (Alawi et al., 2017). More studies are needed to understand whether activation of TRPC4 and TRPC5 can be beneficial in the treatment of joint pain. Apart from inflammation and pain, TRPC channels are also involved in tissue mechanosensing, described in next subchapter.

TRPM

Members of TRPM family, grouped into TRPM1/3, TRPM2, TRPM4/5, TRPM6/7 and TRPM8 subfamilies, play an important role in various cellular processes, including cell proliferation, cell survival and sensing of stress. TRPM2 can be activated by reactive oxygen species (ROS), especially by H2O2 functioning as a sensor for oxidative stress (Fonfría et al., 2004). A typical microenvironment of chondrocytes and IVD cells is hypoxic, but concentration of ROS in cartilage and IVD increases with aging and degeneration (Feng et al., 2017). However, the sensors for ROS in these cells remain unknown. If TRPM2 would function as a receptor for ROS in chondrocytes and IVD cells, targeting its expression and activity could reduce sensitivity of these cells to oxidative stress-induced aging and degeneration. TRPM8 is widely expressed, most abundantly in a subset of pain and temperature sensitive neurons, involved in hyperalgesia and noiception (Behrendt et al., 2004). Neuronal TRPM8 could possibly also transmit pain in joint disorders, but evidence is lacking.

TRP channels in joint mechanosensing and osmosensing

Physiological mechanical load and balanced osmolarity are crucial for the normal function of chondrocytes and IVD cells. Joints and IVDs are under the influence of complex mechanical loads, with every structural part taking over different loading patterns. Their ability to withstand the applied loads gradually decreases throughout the...
individual’s lifetime, leading to the development of pain (Inoue and Espinoza Orias, 2011; Thakur et al., 2014). However, the molecular basis of how these tissues respond to their osmotic and mechanical environments is not fully understood.

Articular cartilage and IVDs are complex structures, composed of water (60-80%), ECM (20-40%) and a small number of cells (1-3%) (Sophia Fox et al., 2009; Urban and Roberts, 2003). Both articular cartilage and IVDs contain a collagen fibre network placed under tension by the swelling pressure of proteoglycans dispersed within these tissues. Collagen type I provides tensile resistance to the applied loads, whereas collagen type II supports the maintenance of an adequate osmotic pressure induced by proteoglycans (Cramer and Darby, 1997; Le Maître et al., 2007; Maroudas, 1976; Sophia Fox et al., 2009; Urban and Roberts, 2003). Proteoglycans possess negative fixed charges electrically balanced, by positive cations, mainly potassium and sodium, located in the interstitial fluid. Upon application of a load, the tissue loses water, while removal of the applied load causes rapid rehydration due to the presence of positively charged ions, creating osmotic gradients (Cramer and Darby, 1997; Galbusera et al., 2014; Han et al., 2011; Urban and Roberts, 2003). Thus, the presence of proteoglycans provides cartilage and IVDs with the ability to resist the compressive loads.

The complex interplay of magnitude, duration and frequency of the mechanical loads determines subsequent osmolarity-mediated biological alterations in articular cartilage and IVD tissue. Physiological mechanical loading can restore the biochemical properties of both tissues, while underloading and overloading reduce tissue function (Gawri et al., 2014; Setton and Chen, 2006; Verteramo and Seedhom, 2007; Wang et al., 2013). ECM turnover is regulated by MMPs and ADAMTS and it is affected by age and degeneration, as the ability of cartilaginous tissues to maintain the ECM declines when both factors increase (Francuski et al., 2014; Illien-Junger et al., 2010; Le Maître et al., 2004; Molinos et al., 2015; Pauli et al., 2011; Sztralovics et al., 1997; Wuertz et al., 2009; Yin and Xia, 2014).

The effect of osmolarity on the turnover of articular cartilage and IVD ECM is well documented (Amin et al., 2011; Ishihara et al., 1997; Johnson et al., 2014; Wuertz et al., 2007). In contrast to other tissues, osmolarity in healthy cartilage and IVDs raises to 430 mOsm/kg, due to the presence of proteoglycans (Ishihara et al., 1997; van Dijk et al., 2011). In vitro cell and organ culture studies, performed in hypoosmotic (300-350 mOsm/kg), isosmotic (400-450 mOsm/kg) and hyperosmotic (500-600 mOsm/kg) conditions, show that both hypoosmotic and hyperosmotic environments alter the gene expression of structural ECM proteins and reduce water and biochemical content of cartilage and IVDs ECM (Chen et al., 2002; Li et al., 2016; Negoro et al., 2008; van Dijk et al., 2011; Wuertz et al., 2007). Interestingly, a hypoosmotic environment is more detrimental than hyperosmotic conditions: application of hyperosmotic saline solution (600 mOsm/kg) in articular cartilage explants reduces cell death after mechanical injury, when compared to normal (hypoosmotic) saline solution (285 mOsm/kg) (Amin et al., 2011). The osmotic environment surrounding chondrocytes and IVD cells is gradually altered during cartilage degeneration and aging, mainly due to a loss of proteoglycans (Adams and Roughley, 2006; Inoue and Espinoza Orias, 2011; Zhou et al., 2016). Therefore, balancing the age- and degeneration-related loss of accurate osmolarity is an important aim in the prevention and treatment of OA and DDD. However, it is yet not completely explained how chondrocytes and IVD cells sense their microenvironment and react to its changes. Uncovering cell surface receptors that are responsible for sensing local ECM structure/composition and transformation of this information into cell responses is the first step in osmo-related drug development. Depending on their functionality, these receptors could then be inhibited or activated to balance the loss of osmolarity.

Both mechanically- and osmotically-induced volume change causes cell membrane stretch or ruffling, influencing cellular Ca\(^{2+}\) homeostasis by exposing or opening and closing Ca\(^{2+}\) channels (Degala et al., 2012; Liu and Montell, 2015). Swollen IVD cells and chondrocytes with a stretched plasma membrane are significantly more sensitive to Ca\(^{2+}\) influx than cells in isosmotic conditions (Pritchard and Guilak, 2004; Zhou et al., 2016). In chondrocytes, hypoosmotic shock causes rapid opening of stretch-activated cation (SAC) channels and TRPV channels, by activating the phospholipase C (PLC)-inositol 1,4,5-triphosphate (IP3) pathway (Sanchez et al., 2003). Responses of chondrocytes and IVD cells to varying extracellular osmolarity and the resulting Ca\(^{2+}\) level changes are mediated by calcineurin-independent transcription factor NFAT5 (ToneEBP), which controls cellular homeostasis through expression of aquaporin 2, collagens, aggrecan, HSP70 and other targets including pro-inflammatory cytokines (Cheung and Ko, 2013; Gaighate et al., 2009; Johnson et al., 2014; Tsai et al., 2006). Furthermore, phospholipase C-γ1 (PLC-γ1)-mediated activation of NFAT5 can contribute to NFAT5 transcriptional activity in HEK293 cells, under elevated NaCl conditions, suggesting a link between TRP channels and NFAT5 (Irarrazabal et al., 2010). However, relevant signalling pathways remain yet to be identified. Current results and hypotheses on how mechanical loading and osmolarity can regulate or be regulated by TRP channels are described below and in Fig. 2.

TRPV
TRPV2 is expressed in chondrocytes (Asmar et al., 2016) and IVD cells (Zvick, 2017), but little is known about its functional relevance in joint diseases. In retinal arterioles and cardiomyocytes, this channel is activated by stretching (Aguetta et al., 2017; McGahon et al., 2016), supporting its emerging
mechanosensor properties. Overexpression or overactivation of TRPV2, by non-physiological stretching in chondrocytes or IVD cells surrounded by degenerated ECM, could cause calcium overload that promotes cell deterioration and death (Berridge et al., 2000; Iatridis et al., 2006). Investigating the role of TRPV2 in mechanically-challenged tissues and organs, such as joints, is clearly warranted (Katanosaka et al., 2014).

TRPV4 is a major osmolarity-regulated ion channel in chondrocyte membranes, whose deletion accelerates the progression of OA in animal models (Clark et al., 2010; Kohler and Hoyer, 2007). In porcine articular chondrocytes, TRPV4-mediated Ca²⁺ signalling regulates osmolarity-induced volume change and subsequent release of prostaglandin E2 (PGE2), a mediator of hyperalgesia (Phan et al., 2009). The same cells treated with IL-1β show an impaired regulatory volume decrease in hypotonic conditions, being unable to reduce their size to counteract hypotonic swelling. Interestingly, this IL-1β-induced effect is eliminated upon TRPV4 activation, indicating that TRPV4 may be involved in modulating inflammation in response to osmotic stress (Phan et al., 2009). In NP cells, reduced osmolarity activates the expression of TRPV4 and at the same time induces TRPV4-mediated Ca²⁺ signalling and gene expression of pro-inflammatory cytokines. Albeit based on the analysis of only one sample, it is proposed that TRPV4 expression is elevated in regions of aggrecan depletion in degenerated human IVD, indicating that TRPV4 can possibly play a role in swelling-related IVD inflammation and ECM breakdown (Walter et al., 2016). The authors suggest that reduced tissue osmolarity, following proteoglycan degradation, can increase TRPV4 signalling, enhance pro-inflammatory cytokine production and contribute to progressive matrix breakdown (Walter et al., 2016). The mechanism of osmolarity-dependent TRPV4 gene expression in chondrocytes includes phosphorylation of ERK1/2 (Hdud et al., 2014) and possibly also osmolarity-associated NFAT5 expression, but the role of NFAT5 in TRPV4-mediated effects has not yet been investigated.

Furthermore, TRPV4 plays a central role in chondrocyte responses to dynamic loading: inhibition of TRPV4 during dynamic loading of porcine agarose-embedded articular chondrocytes prevents expression of anabolic and anti-catabolic genes and reduces the loading-induced production of ECM (O’Conor et al., 2014). Interestingly, chemical activation of TRPV4 in the absence of mechanical loading has similar effects (O’Conor et al., 2014). As is apparent from aforementioned studies, activation of TRPV4 in chondrocytes can have both negative and positive effects. Current findings indicate that cellular consequences of TRPV4 activation depend on the surrounding ECM condition and that tight regulation of TRPV4-mediated Ca²⁺ signalling is important for the correct transduction of osmotic and mechanical signals in chondrocytes (O’Conor et al., 2014). Therefore, it can be suggested that balanced therapeutic desensitisation or partial inhibition of dysregulated TRPV4-mediated osmotransduction and mechanotransduction, rather than total TRPV4 knockout/inhibition, can restore function of the ECM in treatments targeting cartilage or IVDs, including tissue-engineering approaches.

TRPV5/6 are highly Ca²⁺ selective and tightly regulated by intracellular Ca²⁺ concentration (van Abel et al., 2005). TRPV6 knockout mice suffer from severe osteoarthritis and loss of proteoglycans in articular cartilage (Song et al., 2017). Interestingly, reduced expression of TRPV6 was recently found in human OA cartilage and in rat OA model (Song et al., 2017), suggesting that TRPV6 deficiency affects chondrocyte function and homeostasis. Although it is known that TRPV-deficient mice suffer from osteopenia (Chen et al., 2014), very few data on the effects of TRPV6 dysregulation in the spinal connective tissue are available. TRPV6 expression is detected in IVD cells, but its exact role in IVD mechanosensing remains unclear (Zvick, 2017). As TRPV6 is clearly involved in regulating Ca²⁺ homeostasis of bone, its dysregulation may hypothetically aggravate Modic changes (Modic et al., 1988) of vertebral trabeculae or calcification of the endplates, both of which influence IVDs homeostasis and load distribution.

**TRPC**

It is suggested that members of TRPC family, particularly TRPC1 and TRPC6 are mechanically-gated and activated by tension across the lipid bilayer (Garrison et al., 2012; Maroto et al., 2005; Spassova et al., 2006). Mechanical stress at the plasma membrane is also shown to activate TRPC5 (Shen et al., 2015).

TRPC1, TRPC3 and TRPC6 are expressed in chondrocytes (Gavenis et al., 2009) and IVD cells (Zvick, 2017), but their relevance for mechanosensing in OA and DDD remains largely unknown. It is suggested that balanced TRPC6 expression in chondrocytes is associated with phenotypic stability (Web Ref. 1), while TRPC6 overexpression in IVD cells correlates with cell differentiation and senescence (preliminary data). In murine chondrocytes, TRPC6 activation and subsequent calcium flux increases Akt phosphorylation and the expression of key molecular markers, suggesting TRPC6 as a possible therapeutic target in the prevention of articular cartilage breakdown during OA (Web Ref. 2). As multiple TRPC channels are mechanosensitive and a little is known about their relevance in OA and DDD, their therapeutic relevance should clearly be further investigated.

**TRP channels as therapeutic targets in joints**

TRP channels are involved in various aspects of cellular homeostasis, being attractive therapeutic targets if dysregulated. Impairment in TRP channels can be caused by inherited or acquired abnormalities in gene expression, post-transcriptional and post-translational modifications or dysfunction of factors
regulating the activity of TRP channels, many of which are unknown. Most conclusive data are available on the pathomechanisms of hereditary TRP-linked diseases (Nilius and Owsianik, 2010). The current understanding of acquired TRP channel disorders is limited, as it is mainly based on in vitro studies or rodent models, which do not always well represent human diseases (Kaneko and Szallasi, 2014).

One of the major challenges in treating TRP-linked disorders is related to the development of subtype-specific drugs (Moran et al., 2011). In addition to regulating a specific TRP channel, currently available antagonists and agonists often affect several other TRP channels in an unspecific manner, causing side effects (Kaneko and Szallasi, 2014). The function of TRP channels is also tissue-specific, as certain TRP channels can occur at different densities on different cell types. Therefore, not every tissue is affected in the same way by channel dysregulation. As an example, blockage of TRPM4 may be beneficial for the treatment of multiple sclerosis and anaphylaxis, but it may also cause cardiac arrhythmias and hypertension (Nilius and Voets, 2013). This problem can be partially solved by directing TRP drugs into specific tissues by using drug delivery systems targeting a specific cell type. In the treatment of pain, an interesting approach can be to target specifically primary sensory nociceptors by introducing a charged, membrane non-permeable lidocaine derivative (QX-314), together with the TRPV1 activator capsaicin, through the TRPV1 pore. Upon activation and pore opening by capsaicin, QX-314 is taken up, specifically targeting sodium channels and inducing anaesthesia. This system shows promising effects on hyperalgesia in rats (Binshtok et al., 2007). Despite the challenges, several TRP agonists and antagonists have advanced to clinical trials (Kaneko and Szallasi, 2014). Another attractive approach to control overexpression and activation of TRP channels can be patient-specific, targeted genome editing techniques, such as CRISPR/Cas9, with minimised side effects. Detailed description of different TRP-targeting strategies was beyond the scope of this review and can be found in other review articles referenced in this chapter.

For joint disorders, inhibition of pain and improvement in quality of life is the most important result. OA and IVD-related pain is often caused by: (1) ingrowth of sensory nerve fibres into originally aneural tissue, (2) increased production and accumulation of nociceptive molecules, such as cytokines or neuropeptides, in affected joints and (3) tissue damage resulting from reduced mechanical stability. TRPA1 and TRPV1 are functionally expressed on sensory neurons, mediating nociceptive and neuropathic pain responses through interaction with algicес molecules that have accumulated in affected joints. Therefore, inhibition of neuronal TRPA1 and TRPV1 in OA and DDD can possibly alleviate pain symptoms. Selective agonists and antagonists of TRPA1 and TRPV1 are available and being tested as analgesics in pre-clinical and clinical trials for neuropathic and OA pain (Brito et al., 2014; Chen and Hackos, 2015; Moran et al., 2011). Challenges that may be associated with systemic use of these compounds are impaired sensing mechanisms in non-target tissues (e.g., reduced avoidance of pain) or side effects related to possible non-specificity (burning, itching). Local delivery of these compounds into OA joints and degenerated IVDs can substantially reduce their adverse effects. As an example, patches containing high-concentration of the TRPV1 agonist capsaicin, providing rapid and long-lasting pain relief in various neuropathic pain conditions, are already approved by the food and drug administration (FDA) (Baranidharan et al., 2013). Despite current efforts, pain inhibition treatments do not always target underlying pathophysiological mechanisms, allowing degenerative joint diseases to progress. Therefore, antagonising TRPA1 and TRPV1 on sensory neurons may reduce OA and DDD-related pain, but will not counteract joint degeneration. Evidence suggest that TRPA1 and TRPV1 expressed on other cell types, such as chondrocytes, can modulate mechanisms of inflammation (Fernandes et al., 2012). Specific targeting of inflammatory responses mediated by these channels in non-neuronal cells could possibly slow-down disease progression and, in unison, reduce all main pain mechanisms.

Overexpression of other TRP channels, such as TRPV4 or TRPC6, on chondrocytes may possibly lead to detrimental calcium overload or amplification of harmful signals, such as those induced by low pH or ROS, whereas under expression may cause a lack of homeostatic signals from ECM. TRPV4 is involved in cell-ECM communication in chondrocytes and IVD cells, as it senses the local osmotic environment and regulates cellular responses to microenvironmental changes in normal and degenerated joints (McNulty et al., 2015). Therefore, TRPV4 is a promising research candidate and possible therapeutic target in the treatment of age-related loss of ECM function in cartilaginous tissues. Also, TRPC6 may represent a useful target when aiming to prevent degenerative matrix changes or dedifferentiation of chondrocytes and IVD cells, specifically in the context of regenerative cell therapy, when phenotypic stability and reduction of senescence is crucial. Evidence suggests that other interesting targets, including TRPC1, TRPC3, TRPC4, TRPC5, TRPV6, TRPM2, TRPM7 and TRPM8, are possibly implicated in inflammation and mechanosensing in OA and DDD. In the treatment of OA and DDD, significantly dysregulated TRP channels (e.g., TRPA1, TRPV1 and TRPV4) can be therapeutically targeted using agonists/antagonists or genome editing methods. However, the treatment may be more challenging in case of other TRP channels (e.g. members of TRPC family), where a balance among several TRP channels may be more important than complete inhibition or activation of one channel. In such cases, smart
drug delivery systems providing sustained release of multiple drugs or environmentally-responsive systems (e.g. drug release upon reduced osmolarity) may help solving the problem.

Conclusions

TRP channels are involved in sensing and regulation of osmotic, mechanical and inflammatory stress and pain in various tissues. Dysregulation of TRP channels is implicated in multiple diseases, such as cardiovascular disease, muscle dystrophies and possibly joint pathologies. As OA and DDD strongly correlate with mechanical and osmotic stress and inflammation, TRP channels are likely affected. Multiple TRP channels are expressed in chondrocytes and IVD cells. Furthermore, dysregulation of several TRP channels is linked with arthropathies, e.g. TRPA1 and TRPV1 with joint pain and inflammation and TRPV4 with reduced mechanical stability. However, the exact role of TRP channels in OA and DDD remains largely unexplored. We proposed that TRP channels can possibly constitute a link between mechanosensing, osmosensing and inflammatory regulation in chondrocytes and IVD cells and that the patient’s age, genetic background, degree of degeneration and exogenous stress can influence specific TRP-mediated effects in OA and DDD. The interplay between molecular mechanisms underlying degeneration of cartilaginous tissues and TRP channels, as well as, the role of dysregulated TRP channels in OA and DDD, warrant further investigation. Hence, the significance of TRP channels, as therapeutic targets for the treatment of OA and DDD, should be assessed.

Acknowledgements

Financial support was obtained from the Swiss National Science Foundation (SNF PP00P2_163678/1), as well as, from the Spine Society of Europe (Eurospine 2016_4).

References


www.ecmjournal.org


TRP channels in joint diseases


Zvick J (2017) The role of TRP channels in inflammation of intervertebral discs. Master Thesis, Archive of Department of Health Sciences and Technology, ETH Zurich, Hoenggerbergring 64, 8093 Zurich, Switzerland.

Web References


Discussion with Reviewers

Zhen Li: According to Birnbaumer (2009), most KO phenotypes are quite moderate, suggesting that TRP isoforms are able to compensate for the lack of a specific channel. This suggests that none of the TRP member is specifically related to a certain function and would make it extremely difficult to use TRP channels as therapeutic targets. What has been done or can be done in the future to solve this issue?

Author: The main challenge in using TRP channels as therapeutic targets is, indeed, their versatility and diverse (possibly tissue-specific) functionality. These features may allow TRP channels to compensate for each other’s function, resulting in moderate phenotypes in TRP KO mice. Although most mouse TRP KO phenotypes are not lethal, they are associated with certain pathologies. For example, the genetic KO of TRPV4 results in the development of OA and the KO of TRPA1 decreases hypersensitivity and inflammatory responses (Horváth et al., 2016; O’Conor et al., 2013). Chemical activation of these channels leads to opposite effects (McNulty et al., 2015), suggesting specific relationship between these channels and particular pathologies, as well as, possibility for therapeutic targeting.

Versatility of some TRP channels may, indeed, reduce the efficiency of TRP-specific drugs or generate unwanted adverse effects. For example, therapeutic targeting of a single member of the TRPC family can disturb the balance among several

www.ecmjournal.org
TRPC members, which is likely more important than complete inhibition or activation of one TRPC channel. This challenge may be overcome by using specific combinations of TRP channel agonists and antagonists, smart drug delivery systems, providing their sustained release in a particular cell type, environmentally-responsive systems (e.g. drug release upon reduced osmolarity) or targeted genome editing techniques.

Currently, the understanding of which TRP channels are important for signaling in chondrocytes and what TRP-related mechanisms are altered in joint diseases is not complete. Upon uncovering the exact role of TRP channels in cartilage and IVD, it will be possible to assess confidently their potential therapeutic significance.

**Zhen Li**: Compared to other potential targets, do you consider TRP channels as more promising therapeutic targets for pain alleviation in joint disease and disc degenerative disease?

**Authors**: It is possible. One hypothesis can be that certain TRP channels, for example TRPA1 and TRPV1, are (over)expressed both in sensory neurons and chondrocytes/IVD cells, with presumably different functions. We hypothesised that inhibition of these overexpressed or overactivated TRP channels on neurons would alleviate pain, whereas their inhibition in chondrocytes/IVD cells might have different effects, for example reduced inflammation and slower degeneration. Furthermore, one can speculate that the inhibition of a cell receptor can be easier and more specific than the inhibition of all possible activators of this receptor. As an example, antagonising the receptor for IL-1β in cartilaginous tissues can be more promising and less time consuming than developing inhibitors for all known activators of IL-1β-regulated pathways.

**Editor note**: The scientific editor for this paper was Mauro Alini.